Emergent BioSolutions Reports First Quarter 2024 Financial
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of...
Stay updated with breaking news from Assal Hellmer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of...
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance ...
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and...
GAITHERSBURG - Emergent BioSolutions Inc. will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business...
GAITHERSBURG, Md., April 22, 2024 -- Emergent BioSolutions Inc. will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first...